Published in Cancer Res on July 15, 1993
A novel type of cellular senescence that can be enhanced in mouse models and human tumor xenografts to suppress prostate tumorigenesis. J Clin Invest (2010) 3.47
Phosphorylation-dependent ubiquitylation and degradation of androgen receptor by Akt require Mdm2 E3 ligase. EMBO J (2002) 3.27
Linkage analysis of 49 high-risk families does not support a common familial prostate cancer-susceptibility gene at 1q24-25. Am J Hum Genet (1997) 1.68
BK virus as a cofactor in the etiology of prostate cancer in its early stages. J Virol (2007) 1.29
BRAF activation initiates but does not maintain invasive prostate adenocarcinoma. PLoS One (2008) 1.28
GADD45 proteins: central players in tumorigenesis. Curr Mol Med (2012) 1.26
Targeting prostate cancer based on signal transduction and cell cycle pathways. Cell Cycle (2008) 1.25
Loss of PTEN is associated with aggressive behavior in ERG-positive prostate cancer. Cancer Epidemiol Biomarkers Prev (2013) 1.17
Prognostic significance of Bcl-2 in clinically localized prostate cancer. Am J Pathol (1996) 1.13
Intratumor cellular heterogeneity and alterations in ras oncogene and p53 tumor suppressor gene in human prostate carcinoma. Am J Pathol (1995) 1.12
A mouse model of heterogeneous, c-MYC-initiated prostate cancer with loss of Pten and p53. Oncogene (2011) 1.10
Cytokine genetic polymorphisms and prostate cancer aggressiveness. Carcinogenesis (2009) 1.09
Proliferation- and apoptosis-associated factors in advanced prostatic carcinomas before and after androgen deprivation therapy: prognostic significance of p21/WAF1/CIP1 expression. Br J Cancer (1999) 1.07
The genomic landscape of prostate cancer. Front Endocrinol (Lausanne) (2012) 1.07
Molecular markers for prostate cancer metastasis. Developing diagnostic methods for predicting the aggressiveness of prostate cancer. Am J Pathol (1997) 1.06
Alterations in the p53 and MDM-2 genes are infrequent in clinically localized, stage B prostate adenocarcinomas. Am J Pathol (1994) 1.03
Molecular genetic evidence for different clonal origins of epithelial and stromal components of phyllodes tumor of the prostate. Am J Pathol (2004) 0.99
Prostate cancer: Re-focusing on androgen receptor signaling. Int J Biochem Cell Biol (2007) 0.99
Prognostic value of abnormal p53 expression in locally advanced prostate cancer treated with androgen deprivation and radiotherapy: a study based on RTOG 9202. Int J Radiat Oncol Biol Phys (2007) 0.99
DNA damage response genes and the development of cancer metastasis. Radiat Res (2014) 0.93
Mouse models of prostate cancer: picking the best model for the question. Cancer Metastasis Rev (2014) 0.93
Heterogeneity in intratumor distribution of p53 mutations in human prostate cancer. Am J Pathol (1995) 0.92
Molecular pathways in prostate cancer. Nephrourol Mon (2013) 0.92
Prostate cancer progression. Implications of histopathology. Am J Pathol (1994) 0.91
Simultaneous haploinsufficiency of Pten and Trp53 tumor suppressor genes accelerates tumorigenesis in a mouse model of prostate cancer. Differentiation (2008) 0.91
Enhanced tumor suppression in vitro and in vivo by co-expression of survivin-specific siRNA and wild-type p53 protein. Cancer Gene Ther (2010) 0.90
Aberrant expression of DeltaNp73 in benign and malignant tumours of the prostate: correlation with Gleason score. J Clin Pathol (2005) 0.86
Krüppel cripples prostate cancer: KLF6 progress and prospects. Am J Pathol (2003) 0.86
Exosomes in prostate cancer: putting together the pieces of a puzzle. Cancers (Basel) (2013) 0.85
Lymph node status as a guide to selection of available prognostic markers in breast cancer: the clinical practice of the future? Diagn Pathol (2006) 0.85
Clinical impact of TP53 alterations in adrenocortical carcinomas. Langenbecks Arch Surg (2011) 0.84
p53 expression controls prostate cancer sensitivity to chemotherapy and the MDM2 inhibitor Nutlin-3. Cell Cycle (2012) 0.83
Prognostic role of microRNA-145 in prostate cancer: A systems review and meta-analysis. Prostate Int (2015) 0.79
The in vivo role of the RP-Mdm2-p53 pathway in signaling oncogenic stress induced by pRb inactivation and Ras overexpression. PLoS One (2011) 0.79
Tumor suppression and apoptosis of human prostate carcinoma mediated by a genetic locus within human chromosome 10pter-q11. Proc Natl Acad Sci U S A (1996) 0.79
Nuclear iASPP may facilitate prostate cancer progression. Cell Death Dis (2014) 0.79
A microdissection approach to detect molecular markers during progression of prostate cancer. Br J Cancer (1995) 0.78
Radiosensitization of prostate cancer by priming the wild-type p53-dependent cellular senescence pathway. Cancer Biol Ther (2007) 0.77
Adenoviral gene therapy, radiation, and prostate cancer. Rev Urol (2005) 0.77
Significance of p53 and ki-67 expression in prostate cancer. Urol Ann (2015) 0.77
Inflammation contributes to NKX3.1 loss and augments DNA damage but does not alter the DNA damage response via increased SIRT1 expression. J Inflamm (Lond) (2015) 0.77
Prostate Cancer - Old Problems and New Approaches. (Part II. Diagnostic and Prognostic Markers, Pathology and Biological Aspects). Pathol Oncol Res (1996) 0.76
Comparison of digital image analysis and visual scoring of KI-67 in prostate cancer prognosis after prostatectomy. Diagn Pathol (2015) 0.76
Association between AgNORs and Immunohistochemical Expression of ER, PR, HER2/neu, and p53 in Breast Carcinoma. Patholog Res Int (2011) 0.75
Molecular genetics of prostate cancer: clinical applications. J Natl Med Assoc (1998) 0.75
Pathogenesis of prostate cancer: lessons from basic research. Ochsner J (2008) 0.75
Nucleolar GTP-binding Protein-1 (NGP-1) Promotes G1 to S Phase Transition by Activating Cyclin-dependent Kinase Inhibitor p21 Cip1/Waf1. J Biol Chem (2015) 0.75
Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol (1999) 11.18
Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med (2000) 4.67
Aberrant subcellular localization of BRCA1 in breast cancer. Science (1995) 3.61
Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes. Proc Natl Acad Sci U S A (1998) 2.55
Multiple-marker immunohistochemical phenotypes distinguishing malignant pleural mesothelioma from pulmonary adenocarcinoma. Hum Pathol (1993) 2.42
Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer. J Clin Oncol (1999) 2.32
Analysis of loss of heterozygosity in 399 premalignant breast lesions at 15 genetic loci. J Natl Cancer Inst (1998) 2.06
Enhancement of insulin-like growth factor signaling in human breast cancer: estrogen regulation of insulin receptor substrate-1 expression in vitro and in vivo. Mol Endocrinol (1999) 2.00
How to use prognostic factors in axillary node-negative breast cancer patients. J Natl Cancer Inst (1990) 1.95
Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. J Natl Cancer Inst (1995) 1.91
Significance of axillary lymph node metastasis in primary breast cancer. J Clin Oncol (1999) 1.89
A hypersensitive estrogen receptor-alpha mutation in premalignant breast lesions. Cancer Res (2000) 1.86
Acquired tamoxifen resistance: correlation with reduced breast tumor levels of tamoxifen and isomerization of trans-4-hydroxytamoxifen. J Natl Cancer Inst (1991) 1.84
Risk of pulmonary complications after elective abdominal surgery. Chest (1996) 1.84
Genetic aberrations detected by comparative genomic hybridization predict outcome in node-negative breast cancer. Am J Pathol (1995) 1.81
Breast cancer outcome and predictors of outcome: are there age differentials? J Natl Cancer Inst Monogr (1994) 1.79
Congenital anomalies and anthropometry of 42 individuals with deletions of chromosome 18q. Am J Med Genet (1999) 1.76
Loss of heterozygosity at D14S62 and metastatic potential of breast cancer. J Natl Cancer Inst (1999) 1.75
Hormone receptor status of a contralateral breast cancer is independent of the receptor status of the first primary in patients not receiving adjuvant tamoxifen. J Clin Oncol (2005) 1.63
Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice. J Clin Invest (1989) 1.56
Tumor characteristics and clinical outcome of tubular and mucinous breast carcinomas. J Clin Oncol (1999) 1.55
Insulin-like growth factor binding protein-3 and insulin receptor substrate-1 in breast cancer: correlation with clinical parameters and disease-free survival. Clin Cancer Res (1997) 1.54
The small heat shock protein hsp27 is correlated with growth and drug resistance in human breast cancer cell lines. Cancer Res (1993) 1.54
Rising levels of estrogen receptor in breast cancer over 2 decades. Cancer (1994) 1.51
Oxidative stress and AP-1 activity in tamoxifen-resistant breast tumors in vivo. J Natl Cancer Inst (2000) 1.50
Apoptosis and proliferation as predictors of chemotherapy response in patients with breast carcinoma. Cancer (2000) 1.45
Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol (1996) 1.41
Balancing the risks and benefits of genomic data sharing: genome research participants' perspectives. Public Health Genomics (2011) 1.40
Comparative genomic hybridization, allelic imbalance, and fluorescence in situ hybridization on chromosome 8 in prostate cancer. Genes Chromosomes Cancer (1994) 1.37
Incidence and hospital stay for cardiac and pulmonary complications after abdominal surgery. J Gen Intern Med (1995) 1.34
Inhibition of estrogen receptor action by a naturally occurring variant in human breast tumors. Cancer Res (1992) 1.30
Physical mapping of chromosome 8p22 markers and their homozygous deletion in a metastatic prostate cancer. Genomics (1996) 1.27
Prediction of node-negative breast cancer outcome by histologic grading and S-phase analysis by flow cytometry: an Eastern Cooperative Oncology Group Study (2192). Am J Clin Oncol (2001) 1.26
Prognostic value of Ki-67 compared to S-phase fraction in axillary node-negative breast cancer. Clin Cancer Res (1996) 1.26
Molecular genetic studies of early breast cancer evolution. Breast Cancer Res Treat (1994) 1.24
bcl-2, p53, and response to tamoxifen in estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group study. J Clin Oncol (1997) 1.23
Pathological features and BRCA1 mutation screening in premenopausal breast cancer patients. Clin Cancer Res (2001) 1.22
Hsp27 overexpression inhibits doxorubicin-induced apoptosis in human breast cancer cells. Breast Cancer Res Treat (1999) 1.21
bcl-2 and apoptosis in lymph node positive breast carcinoma. Cancer (1998) 1.21
Prognostic significance of p53 gene alterations in node-negative breast cancer. Breast Cancer Res Treat (1993) 1.20
HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group Study. Clin Cancer Res (1998) 1.20
Phase I and pharmacokinetic trial of weekly CPT-11. J Clin Oncol (1993) 1.20
cDNA expression arrays reveal incomplete reversal of age-related changes in gene expression by calorie restriction. Mech Ageing Dev (2000) 1.20
p53 protein accumulation detected by five different antibodies: relationship to prognosis and heat shock protein 70 in breast cancer. Cancer Res (1994) 1.18
Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas. Clin Cancer Res (1997) 1.17
Increased tumor proliferation and genomic instability without decreased apoptosis in MMTV-ras mice deficient in p53. Mol Cell Biol (1997) 1.17
Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony-forming units in vitro. J Natl Cancer Inst (1992) 1.16
Prediction of clinical outcome from primary tamoxifen by expression of biologic markers in breast cancer patients. Clin Cancer Res (2000) 1.16
The p53 tumor suppressor gene in breast cancer. Breast Cancer Res Treat (1994) 1.15
Prognostic and predictive value of p53 and p21 in breast cancer. Breast Cancer Res Treat (1998) 1.13
A bioavailability and pharmacokinetic study of oral and intravenous hydroxyurea. Blood (1998) 1.13
Differential antigen preservation during tissue autolysis. Hum Pathol (1991) 1.11
AP-1 blockade inhibits the growth of normal and malignant breast cells. Oncogene (2001) 1.10
Correlation of insulin-like growth factor-binding protein-3 messenger RNA with protein expression in primary breast cancer tissues: detection of higher levels in tumors with poor prognostic features. J Natl Cancer Inst (1996) 1.10
Differential expression of the early lung cancer detection marker, heterogeneous nuclear ribonucleoprotein-A2/B1 (hnRNP-A2/B1) in normal breast and neoplastic breast cancer. Breast Cancer Res Treat (2001) 1.10
The prognostic significance of surgical staging for carcinoma of the endometrium. Gynecol Oncol (1992) 1.10
Measure once or twice -- does it really matter? J Natl Cancer Inst (1999) 1.09
Mechanisms of hormonal prevention of breast cancer. Ann N Y Acad Sci (2001) 1.08
Insulin receptor expression and clinical outcome in node-negative breast cancer. Proc Assoc Am Physicians (1997) 1.08
Cathepsin D by western blotting and immunohistochemistry: failure to confirm correlations with prognosis in node-negative breast cancer. J Clin Oncol (1994) 1.07
Cytological evaluation of biological prognostic markers from primary breast carcinomas. Breast Cancer Res Treat (1997) 1.06
Keratin 6a marks mammary bipotential progenitor cells that can give rise to a unique tumor model resembling human normal-like breast cancer. Oncogene (2011) 1.06
Treatment decisions in axillary node-negative breast cancer patients. J Natl Cancer Inst Monogr (1992) 1.06
Developmental and hormonal signals dramatically alter the localization and abundance of insulin receptor substrate proteins in the mammary gland. Endocrinology (2003) 1.05
9-cis-Retinoic acid suppresses mammary tumorigenesis in C3(1)-simian virus 40 T antigen-transgenic mice. Clin Cancer Res (2000) 1.04
The small heat shock protein hsp27 increases invasiveness but decreases motility of breast cancer cells. Invasion Metastasis (1997) 1.04
DNA repair signature is associated with anthracycline response in triple negative breast cancer patients. Breast Cancer Res Treat (2010) 1.02
Early exposure of the rat mammary gland to estrogen and progesterone blocks co-localization of estrogen receptor expression and proliferation. J Endocrinol (2001) 0.99
The ER-positive/PgR-negative breast cancer phenotype is not associated with mutations within the DNA binding domain. Breast Cancer Res Treat (1993) 0.99
Prevalence of Cryptosporidium parvum infection in children along the Texas-Mexico border and associated risk factors. Am J Trop Med Hyg (2000) 0.99
Bcl-2 overexpression is associated with resistance to paclitaxel, but not gemcitabine, in multiple myeloma cells. Int J Oncol (1998) 0.98
Growth factor signalling and response to endocrine therapy: the Royal Marsden Experience. Endocr Relat Cancer (2005) 0.97
Genomic approaches in the management and treatment of breast cancer. Br J Cancer (2005) 0.97
Quantitative changes in cytological molecular markers during primary medical treatment of breast cancer: a pilot study. Breast Cancer Res Treat (1999) 0.97
Heat shock proteins and drug resistance. Breast Cancer Res Treat (1994) 0.96
FISH mapping of de novo apparently balanced chromosome rearrangements identifies characteristics associated with phenotypic abnormality. Am J Hum Genet (2008) 0.96
Expression and functionality of the trkA proto-oncogene product/NGF receptor in undifferentiated hematopoietic cells. Blood (1994) 0.96
Radiation therapy and survival in breast cancer patients with 10 or more positive axillary lymph nodes treated with mastectomy. J Clin Oncol (1998) 0.95
Cancer among Haitians in Florida. Cancer (1987) 0.95
Predictive value of apoptosis, proliferation, HER-2, and topoisomerase IIalpha for anthracycline chemotherapy in locally advanced breast cancer. Breast Cancer Res Treat (2005) 0.94
Mitosin (a new proliferation marker) correlates with clinical outcome in node-negative breast cancer. Cancer Res (1997) 0.94
IGF system components as prognostic markers in breast cancer. Breast Cancer Res Treat (1998) 0.94
Prognostic value of p53 for local failure in mastectomy-treated breast cancer patients. J Clin Oncol (2000) 0.94
Prognostic factors: rationale and methods of analysis and integration. Breast Cancer Res Treat (1994) 0.93
1,25-Dihydroxyvitamin D3 is a potent inducer of nerve growth factor synthesis. J Neurosci Res (1991) 0.93
Changes in hormone receptors and proliferation markers in tamoxifen treated breast cancer patients and the relationship with response. Breast Cancer Res Treat (1998) 0.92
The importance of tamoxifen metabolism in tamoxifen-stimulated breast tumor growth. Cancer Chemother Pharmacol (1994) 0.92
Anergy-like immunosuppression in mice bearing pulmonary foreign-body granulomatous inflammation. Am J Pathol (1985) 0.91
Epstein-Barr virus infection is associated with p53 accumulation in nasopharyngeal carcinoma. Hum Pathol (1998) 0.91
Effects of Taxotere and taxol on in vitro colony formation of freshly explanted human tumor cells. Anticancer Drugs (1992) 0.91
Activity of CPT-11 (irinotecan hydrochloride), a topoisomerase I inhibitor, against human tumor colony-forming units. Anticancer Drugs (1994) 0.91
Inhibition of estrogen-induced breast cancer cell proliferation by reduction in autocrine transforming growth factor alpha expression. Cell Growth Differ (1994) 0.90
WAF1/CIP1 protein expression in human breast tumors. Breast Cancer Res Treat (1997) 0.90
Response: Location of BRCA1 in Human Breast and Ovarian Cancer Cells. Science (1996) 0.90
Frequent gain of chromosome 19 in megakaryoblastic leukemias detected by comparative genomic hybridization. Genes Chromosomes Cancer (2001) 0.90